A new study will explore the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.
The research is being carried out by the Cornea and Laser Eye Institute, with Dr Peter Hersh acting as principal investigator, and the specialists hope it will show how CXL can strengthen the cornea and decrease the progression of keratoconus.
Keratoconus is a disease of the cornea which affects one in 2,000 people and, although special contact lenses exist to tackle the problem, its severity means that these patients may ultimately require corneal transplantation to regain vision.
The experts state: "The goal of the study is to assess the safety and efficacy of crosslinking for the treatment of keratoconus as well as corneal ectasia after LASIK. If successful, CXL may decrease progression of keratoconus and maintain the patient"s vision over time."
In other ophthalmology research, a recent study published in an issue of Archives of Ophthalmology has shown that a course of oral antiviral medication following infection with the herpes simplex virus (HSV) may help to reduce the risk of recurring eye-related manifestations of the disease.
by Emily Tait